Tetraphase Pharmaceuticals (TTPH) announced after the close Tuesday that its Phase 3 study of once-daily intravenous eravacycline compared to ertapenem for the treatment of patients with complicated urinary tract infections did not achieve it co-primary endpoints.
from RTT - Before the Bell http://ift.tt/2EESJSN
via IFTTT
No comments:
Post a Comment